Skip to content
PulseMS
Log inJoin
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Research evidence filters

Filters apply to reviewed research. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesFiltered
Research and community updates, newest first.#OtherClear filters
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 2Trial registry

Safety of Sequential Rituximab and Cladribine Treatment in Relapsing-Remitting MS Patients

The HiHat trial is underway to assess the safety of rituximab followed by cladribine in individuals with relapsing-remitting multiple sclerosis (RRMS). It aims to determine if the rate of serious adverse events (SAEs) is low following this sequential treatment.

What this does not proveResults are not yet available from this Phase 2 trial, and the planned enrollment and endpoints do not constitute findings.
#Other
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 1Trial registry

Ferumoxytol in Brain MRI for Multiple Sclerosis and Healthy Volunteers

In a Phase 1 pilot study, ferumoxytol was evaluated as a safe contrast agent in brain MRI for healthy volunteers and individuals with multiple sclerosis. The safety was demonstrated by the absence of long-term signal changes, and it was found that ferumoxytol enhancement could be observed in MS lesions using a 7-tesla MRI. However, explicit results have not been reported yet.

What this does not proveThe study has no clear results published; it primarily aimed to assess safety and imaging techniques rather than confirm findings.
#Other
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer-reviewed

Association of CHI3L1 rs871799 Genotypes in Human MS Patients

In a study of 240 individuals (123 MS patients and 117 healthy controls), CHI3L1 rs871799 was significantly associated with MS susceptibility, with the CG + GG genotypes more frequent in MS patients. Differences in genotype distributions were found between relapse-remitting MS (RRMS) and progressive forms of MS, suggesting a correlation with clinical phenotype and neurological disability.

What this does not proveThe results are exploratory and must be interpreted with caution due to a small number of progressive MS patients and the combination of SPMS and PPMS in the analysis. Additionally, a cross-sectional assessment limits insight into the progression of disability over time.
#Other
View abstract on PubMedPMID 42842194AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 3Trial registry

Phase 3 Study of Orelabrutinib in Human Patients with Secondary Progressive Multiple Sclerosis

A Phase 3 clinical trial is being conducted to assess the efficacy and safety of orelabrutinib, compared to a placebo, in approximately 990 patients with non-active secondary progressive multiple sclerosis (SPMS). Participants will be randomly assigned to orelabrutinib or placebo groups over a treatment period of 24 to 60 months, focusing on the time to confirmed disability progression.

What this does not proveThe study is still in the recruitment phase, and results have not yet been published. Thus, there is no evidence of effectiveness or safety at this time.
#Other
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studySystematic reviewPeer-reviewed

Surgical Interventions for Trigeminal Neuralgia in Multiple Sclerosis (Human Subjects)

A systematic review of 32 studies involving 1617 patients evaluated surgical interventions for trigeminal neuralgia in multiple sclerosis. Findings indicated microvascular decompression had durable outcomes but higher complication risks, while partial sensory rhizotomy and percutaneous ablative procedures showed high initial success rates. Gamma knife radiosurgery's durability was variable, and preliminary outcomes for arachnoid-trigeminal nerve release suggested a 75% success rate.

What this does not proveThe study did not employ a quantitative meta-analysis, limiting statistical depth. Additionally, there is diagnostic uncertainty regarding pain specifically attributable to multiple sclerosis, which adds complexity to treatment planning. Higher procedural risks reinforce the necessity for individualized treatment approaches.
#Other
View abstract on PubMedPMID 42839184AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Ocrelizumab and Infection Risks in Older Adults with MS

A study found that ocrelizumab treatment in older adults with MS led to higher rates of hospitalization due to infections (IRR 1.67) and overall infection rates (IRR 1.42) compared to unexposed older MS adults, after a median follow-up of 3.5 years.

What this does not proveThe study excluded younger adults, which may limit its applicability to the broader MS population. Additionally, its retrospective design might introduce bias in the data interpretation.
#Other
View abstract on PubMedPMID 42834886AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 2Peer review unconfirmed

Lacosamide Effects on Pain Management in Human MS Patients

In a Phase 2 randomized trial, lacosamide reduced pain severity in MS patients significantly compared to placebo (P = 0.001), with 90% of participants on lacosamide reporting improvements. Additional benefits included reduced pain interference, total NPSI scores, and enhanced SF-36 scores, with no serious side effects reported.

What this does not proveThe study lacked details on sample size and specific methodological aspects, limiting the interpretation of these results.
#Other
View abstract on PubMedPMID 42832970AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedPhase 3Peer review unconfirmed

Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials

In a study of 1656 patients with relapsing MS, continuous treatment with ocrelizumab (OCR) over 10 years reduced the risk of 48-week confirmed disability progression by 24% compared to those who started treatment later with interferon (IFN). Most patients on OCR remained disability-free and experienced lowered relapse rates over time without an increase in serious adverse events.

What this does not proveThe study does not establish the effects of ocrelizumab beyond 10 years or evidence of its efficacy in individuals outside the study population.
#Other
View abstract on PubMedPMID 42832215AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedPeer review unconfirmed

Human RRMS Patients' Mitochondrial DNA Analysis

In a study of 100 patients with relapsing-remitting multiple sclerosis (RRMS), whole mitochondrial DNA (mtDNA) was sequenced. No pathogenic mtDNA variants or significant associations with MS risk or progression were found. However, exploratory analyses suggested nominal links between some mtDNA variants and RRMS characteristics such as relapse occurrence and disability level.

What this does not proveThe study found no significant role of mtDNA variants in RRMS. The preliminary associations noted are exploratory and require validation in larger, independent cohorts before any conclusions can be drawn about their significance.
#Other
View abstract on PubMedPMID 42831582AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer-reviewed

Peer Support Programs for Individuals with Acquired Neurological Disabilities

A systematic review of 32 studies on peer support for individuals with acquired neurological disabilities, including multiple sclerosis, revealed that participants find value in three areas: capacity-building, social connection, and psychological adjustment. However, they also encounter frustrations that can negate these benefits.

What this does not proveThe review does not quantify the efficacy of peer support specifically for MS or assess individual differences in experiences with peer support in a measurable way.
#Other
View abstract on PubMedPMID 42830590AI summary of a published abstract. Not medical advice.